AstraZeneca's Early-Stage Lung Cancer Tagrisso Drug Approved in China
April 14 2021 - 2:48AM
Dow Jones News
By Sabela Ojea
AstraZeneca PLC said Wednesday that its Tagrisso medicine has
been approved in China for the treatment of early lung cancer.
The U.K.-based pharmaceutical giant said Tagrisso is the first
such drug to have received approval in China, as well as the only
one to have shown efficacy against the disease in a global
trial.
The FTSE 100 company added that the approval is based on the
positive results coming from the Adaura Phase 3 trial, where
Tagrisso was proven to reduce the risk of disease recurrence or
death by 80%.
Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix
(END) Dow Jones Newswires
April 14, 2021 02:33 ET (06:33 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Apr 2023 to Apr 2024
